Cimzia Succeeds in Psoriatic Arthritis

Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston and Dorothy Caputo, MA, BSN, RN, Nurse PlannerAction Points BERLIN -- Response rates to the tumor necrosis factor (TNF) inhibitor certolizumab pegol (Cimzia) among patients with active psoriatic arthritis were twice those seen with placebo in a phase III study, a researcher said here.After 3 months of treatment, 58% of patients receiving certolizumab in doses of 200 mg every other week had achieved

Read more ...